0001209191-20-045930.txt : 20200810 0001209191-20-045930.hdr.sgml : 20200810 20200810161355 ACCESSION NUMBER: 0001209191-20-045930 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200806 FILED AS OF DATE: 20200810 DATE AS OF CHANGE: 20200810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALTSHULER DAVID CENTRAL INDEX KEY: 0001550395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 201089522 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-06 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001550395 ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Global Research and CSO Common Stock 2020-08-06 4 M 0 1223 155.57 A 30125 D Common Stock 2020-08-06 4 S 0 490 270.12 D 29635 D Common Stock 2020-08-06 4 S 0 423 271.39 D 29212 D Common Stock 2020-08-06 4 S 0 310 272.60 D 28902 D Stock Option (Right to Buy) 155.57 2020-08-06 4 M 0 1223 0.00 D 2028-02-05 Common Stock 1223 7338 D Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $270.12 (range $269.73 to $270.58). Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $271.39 (range $270.94 to $271.89). Open market sales reported on this line occurred at a weighted average price of $272.60 (range $272.35 to $272.88). The option vests in 16 quarterly installments from 02/06/2018. /s/ Sabrina Yohai, Attorney-in-Fact 2020-08-10